Epilepsy Pipeline Update 2010 Showcasing New and Promising Epilepsy Therapies

February 25-26 Forum to Bring Together Innovators, Clinicians and Investors

Middleburg, VA, January 12, 2010 — The Epilepsy Therapy Project (ETP), a non-profit organization dedicated to advancing new therapies for people living with epilepsy, announces the Epilepsy Pipeline Update 2010 conference, an in-depth, 2-day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco. The conference will feature a line up of leading innovators, clinical investigators and industry leaders who will offer insights into the discovery and development of pioneering drugs, biologics and devices for epilepsy with the goal of accelerating patient access to new treatments.

The conference will bring together emerging CNS companies and scientific entrepreneurs to present their strategies, product candidates and development programs to potential venture capital, private equity, pharma and biotech investors and partners. Hand-selected by the Scientific and Business Advisory Boards of Epilepsy Therapy Project, presenters will cover the most innovative therapies in development today for epilepsy. Presentations will review products from public companies such as Cyberonics, Eisai, Johnson & Johnson, King Pharmaceuticals, Lundbeck, Medtronic, Sepracor, Valeant Pharmaceuticals and UCB, as well as private companies such as Advanced Neurometrics, Marinus Pharmaceuticals, NeuroPace, NeuroTherapeutics, NeuroVista, Supernus Pharmaceuticals and Visualase. A panel of drug and device experts will address issues of reimbursement.

Presentations on the state of the art in epilepsy drugs and devices will be given by experts Robert Fisher, MD, PhD (Stanford), and Michael Rogawski, MD, PhD (UC Davis). In addition, a special session on bio-markers for epilepsy will focus on proteomics (David Agus, MD, USC), potassium channels (Jeffrey Noebels, MD, PhD, Baylor), and ion channel modulators (Geoffrey Pitt, MD, PhD, Duke University).

“This conference highlights the latest innovations in epilepsy, as well as notable investment and commercial opportunities in the CNS field,” said Warren Lammert, ETP Founder and Chairman and father of a child with epilepsy. “Epilepsy affects as many people as breast cancer or Alzheimer’s disease, and the need for more effective therapies is acutely felt by the million people who continue to have seizures despite available therapies. This event is a unique networking opportunity for all of us involved in the effort to accelerate epilepsy drug and device development.”

Business development, industry executives, venture and crossover investors focused on financing and partnering opportunities in the epilepsy and CNS space, as well as scientists, tech transfer representatives and those interested in emerging drugs in the epilepsy and CNS pipeline, are invited to attend this comprehensive forum. For registration or additional program information, please visit our conference details page at: http://www.epilepsy.com/epilepsy-pipeline-update-portal-cns-0 and see the program at http://www.epilepsy.com/etp/pipeline2010_program.

Please note that early registration fees will be available until January 15, 2010.

The Epilepsy Therapy Project thanks the supporters of the Epilepsy Pipeline Update 2010 conference including Cyberonics, Eisai, Lundbeck, Medtronic, Pfizer, UCB, and Upsher-Smith.

About the Epilepsy Therapy Project
The Epilepsy Therapy Project is a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy. Founded in 2002 by a group of parents, distinguished physicians and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects. Learn more at www.epilepsy.com.